He XY - Search Results

1

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.

Lin YT, Wang C, He XY, Yao QM, Chen J. Lin YT, et al. Among authors: he xy. Front Immunol. 2024 Jan 11;14:1345942. doi: 10.3389/fimmu.2023.1345942. eCollection 2023. Front Immunol. 2024. PMID: 38274823 Free PMC article.

2

Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer.

Chen M, Zhang H, He X, Lin Y. Chen M, et al. Front Pharmacol. 2024 Jul 11;15:1303808. doi: 10.3389/fphar.2024.1303808. eCollection 2024. Front Pharmacol. 2024. PMID: 39055495 Free PMC article.

3

Major adverse events associated with lipid reduction in inclisiran:a pharmacovigilance research of the FAERS database.

Huang ZT, Zhang WH, Wang DZ, Zhang YJ, Duan YB, He XY, Gao YX, Jia ZN, Xu Q. Huang ZT, et al. Among authors: he xy. Expert Opin Drug Saf. 2024 Dec 25. doi: 10.1080/14740338.2024.2446407. Online ahead of print. Expert Opin Drug Saf. 2024. PMID: 39720987

4

Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1.

Zang X, He XY, Xiao CM, Lin Q, Wang MY, Liu CY, Kong LY, Chen Z, Xia YZ. Zang X, et al. Among authors: he xy. Mol Cancer. 2024 Dec 23;23(1):278. doi: 10.1186/s12943-024-02200-x. Mol Cancer. 2024. PMID: 39716144 Free PMC article. No abstract available.

5

Interfacial Field-Effect Enabling High-Performance Perovskite Photovoltaics.

He XY, Wang KL, Chen J, Chen CH, Xia Y, Huang L, Jin RJ, Nizamani N, Su Z, Gao X, Wang ZK. He XY, et al. Small. 2024 Dec 20:e2410310. doi: 10.1002/smll.202410310. Online ahead of print. Small. 2024. PMID: 39703151

6

Monocyte to high-density lipoprotein cholesterol ratio as a predictor of the activity of thyroid-associated ophthalmopathy.

Sun XH, Zhang XW, Han C, Dou X, He XY, Su MR, Jiang F, Yuan ST. Sun XH, et al. Among authors: he xy. Int J Ophthalmol. 2024 Dec 18;17(12):2276-2281. doi: 10.18240/ijo.2024.12.16. eCollection 2024. Int J Ophthalmol. 2024. PMID: 39697873 Free PMC article.

7

Intensive care unit-acquired weakness: Unveiling significant risk factors and preemptive strategies through machine learning.

He XY, Zhao YH, Wan QW, Tang FS. He XY, et al. World J Clin Cases. 2024 Dec 16;12(35):6760-6763. doi: 10.12998/wjcc.v12.i35.6760. World J Clin Cases. 2024. PMID: 39687651 Free PMC article.

8

Prevalence of Helicobacter pylori infection in China from 2014-2023: A systematic review and meta-analysis.

Xie L, Liu GW, Liu YN, Li PY, Hu XN, He XY, Huan RB, Zhao TL, Guo HJ. Xie L, et al. Among authors: he xy. World J Gastroenterol. 2024 Nov 21;30(43):4636-4656. doi: 10.3748/wjg.v30.i43.4636. World J Gastroenterol. 2024. PMID: 39575409 Free PMC article.

9

Surface-engineered mesenchymal stem cell for refractory asthma therapy: Reversing airway remodeling.

He XY, Han MM, Zhao YC, Tang L, Wang Y, Xing L, Wei N, Wang J, Wang GJ, Zhou F, Jeong JH, Jiang HL. He XY, et al. J Control Release. 2024 Dec;376:972-984. doi: 10.1016/j.jconrel.2024.10.056. Epub 2024 Nov 6. J Control Release. 2024. PMID: 39476873

10

Application prospects of urine-derived stem cells in neurological and musculoskeletal diseases.

Yang HS, Zheng YX, Bai X, He XY, Wang TH. Yang HS, et al. Among authors: he xy. World J Orthop. 2024 Oct 18;15(10):918-931. doi: 10.5312/wjo.v15.i10.918. eCollection 2024 Oct 18. World J Orthop. 2024. PMID: 39473520 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

791 results

Search Page

Filters